Company Description
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors.
It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease.
In addition, the company develops MP0621, a molecular partners’ first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates.
Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Country | Switzerland |
| Founded | 2004 |
| IPO Date | Jun 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Patrick Amstutz |
Contact Details
Address: Wagistrasse 14 Schlieren, 8952 Switzerland | |
| Phone | 41 44 755 77 00 |
| Website | molecularpartners.com |
Stock Details
| Ticker Symbol | MOLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| IPO Price | $21.25 |
| CIK Code | 0001745114 |
| CUSIP Number | 60853G106 |
| ISIN Number | US60853G1067 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, Chief Executive Officer, Member of Management Board and Director |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive Vice President of Projects and Member of Management Board |
| Robert Hendriks | Senior Vice President of Finance |
| Alexander Zurcher | Chief Operating Officer and Member of Management Board |
| Renate Gloggner | Executive Vice President of People and Community and Member of Management Board |
| Dr. Philippe Legenne M.B.A., M.D. | Chief Medical Officer and Member of the Management Board |
| Daniel Steiner Ph.D. | Senior Vice President of Research and Technology |
| Seth D. Lewis | Senior Vice President of Investor Relations, Communications and Strategy |
| Michael Pitzner | General Counsel, Compliance Officer, Senior Vice President Legal and Business Development |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | F-3 | Filing |
| Mar 6, 2025 | 6-K | Report of foreign issuer |
| Mar 6, 2025 | 6-K | Report of foreign issuer |
| Mar 6, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jan 13, 2025 | 6-K | Report of foreign issuer |
| Jan 13, 2025 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 28, 2024 | 6-K | Report of foreign issuer |
| Oct 25, 2024 | 424B5 | Filing |